ABSTRACT
Background SARS-CoV2 infection causes severe, life-threatening pneumonia. Hyper-inflammation, coagulopathy and lymphopenia are associated with pathology and poor outcomes in these patients. Cell-free (cf) chromatin is prominent in COVID-19 patients, amplifies inflammation and promotes coagulopathy and immune dysfunction. We hypothesized that cf-chromatin clearance by nebulised dornase alfa may reduce inflammation and improve disease outcomes. Here, we evaluated the efficacy of nebulized dornase alfa in patients hospitalised with severe COVID-19 pneumonia.
Methods In this randomised controlled single-centre phase 2 proof-of-concept trial, we recruited adult patients admitted to hospital that exhibited stable oxygen saturation (≥94%) on supplementary oxygen and a C-reactive protein (CRP) level ≥30mg/L post dexamethasone treatment. Participants were randomized at a 3:1 ratio to receive twice-daily nebulised dornase alfa in addition to best available care (BAC) or BAC alone for seven days or until hospital discharge. A 2:1 ratio of historical controls to treated individuals (HC, 2:1) were included as the primary endpoint comparators. The primary outcome was a reduction in systemic inflammation measured by blood CRP levels over 7 days post-randomisation, or to discharge if sooner. Secondary and exploratory outcomes included time to discharge, time on oxygen, D-dimer levels, lymphocyte counts and levels of circulating cf-DNA.
Results We screened 75 patients and enrolled 39 participants out of which 30 in dornase alfa arm, and 9 in BAC group. We also matched the recruited patients in the treated group (N=30) to historical controls in the BAC group (N=60). For the the primary outcome, 30 patients in the dornase alfa were compared to 69 patients in the BAC group. Dornase alfa treatment reduced CRP by 33% compared to the BAC group at 7-days (P=0.01). The dornase alfa group least squares mean CRP was 23.23 mg/L (95% CI 17.71 - 30.46) and the BAC group 34.82 mg/L (95% CI 28.55 – 42.47). A significant difference was also observed when only randomised participants were compared. Furthermore, compared to the BAC group, the chance of live discharge was increased by 63% in the dornase alfa group (HR 1.63, 95% CI 1.01 – 2.61, P=0.03), lymphocyte counts were improved (least-square mean: 1.08 vs 0.87, P=0.02) and markers of coagulopathy such as D-dimer were diminished (least-square mean: 570.78 vs 1656.96μg/mL, P=0.004). Moreover, the dornase alfa group exhibited lower circulating cf-DNA levels that correlated with CRP changes over the course of treatment. No differences were recorded in the rates and length of stay in the ICU or the time on oxygen between the groups. Dornase alfa was well-tolerated with no serious adverse events reported.
Conclusions In this proof-of-concept study in patients with severe COVID-19 pneumonia, treatment with nebulised dornase alfa resulted in a significant reduction in inflammation, markers of immune pathology and time to discharge. The effectiveness of dornase alfa in patients with acute respiratory infection and inflammation should be investigated further in larger trials.
Trial registration number NCT04359654
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04359654
Funding Statement
This work was supported by LifeArc (UCL-UCLH132333), UCL, Breathing Matters and the Francis Crick Institute which receives its core funding from the UK Medical Research Council (FC0010129), Cancer Research UK (FC0010129) and the Wellcome Trust (FC0010129). The study was undertaken at UCLH/UCL who received a proportion of funding from the Department of Health NIHR Biomedical Research Centres funding scheme. VJS and DB are funded by the NIHR University College London Hospitals Biomedical Research Centre. I.V.A was funded by an EMBO LTF (ALTF 113-2019).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The COVASE trial was sponsored by University College London, carried out at University College London Hospitals (UCLH). The trial protocol and the statistical analysis plan are available in the Appendix. The COVASE trial was reviewed by an Independent Ethics Committee or Institutional Review Board: the South Central - Hampshire B Research Ethics Committee Level 3 Block B Whitefriars Lewins Mead, Bristol BS1 2NT, chaired by Professor Vincenzo Libri (REC reference: 20/SC/0197, Protocol number: 132333, RAS project ID:283091) and the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA). The trial was conducted in accordance with the principles of the Declaration of Helsinki and the ethical guidelines of the Council for International Organizations of Medical Sciences, applicable International Council for Harmonisation Good Clinical Practice guidelines, and applicable laws and regulations. All the randomized participants provided written informed consent. Consent for the historical controls was covered by the Health Service (Control of Participant Information) Regulations 2002 that allows the processing of Confidential Participant Information (CPI) for specific purposes. Regulation 3 provides for the processing of CPI in relation to communicable diseases and other threats to public health and in particular, allows the Secretary of State to require organisations to process CPI for purposes related to communicable diseases. The COVID-19 pandemic is covered by this legislation which allows a range of purposes related to diagnosing, managing, and controlling the spread of COVID-19. The sponsors designed the trial, in collaboration with the investigators at the Francis Crick institute, Exploristics and Target to Treatment Consulting, and the sponsors and trial investigators participated in data collection, analysis, and interpretation. The authors made the decision to submit the manuscript for publication and vouch for the accuracy and completeness of the data presented and for the fidelity of the trial to the protocol. The COVASE study was registered on clinicaltrials.gov identifier: NCT04359654. Safety and data integrity were regularly reviewed by the Trial Monitoring Group and Data Monitoring Committee.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
